Results 11 to 20 of about 315,728 (345)
Journal of the American Medical Association (JAMA), 2021 Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Immunocompromised individuals have been excluded from studies of SARS-CoV-2 messenger RNA (mRNA) vaccines.
B. Boyarsky +6 more
semanticscholar +1 more source
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
New England Journal of Medicine, 2020 Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.
E. Walsh +24 more
semanticscholar +1 more source
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Journal of the American Medical Association (JAMA), 2021 Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited. Objective To
Ai-ris Y. Collier +27 more
semanticscholar +1 more source
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Nature Network Boston, 2021 Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
T. Schmidt +14 more
semanticscholar +1 more source
Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization [PDF]
Frontiers in Immunology, 2021 Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses. The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
Dana N. Thornlow +10 more
openaire +3 more sources
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
New England Journal of Medicine, 2020 Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19 ...
E. Anderson +36 more
semanticscholar +1 more source
Journal of Nanobiotechnology, 2021 Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting ...
Saghi Nooraei +6 more
semanticscholar +1 more source
10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
mAbs, 2020 Therapeutic proteins and emerging gene and cell-based therapies are attractive therapeutic tools for addressing unmet medical needs or when earlier conventional treatment approaches failed.
S. Tourdot +17 more
doaj +1 more source
Nature Communications, 2021 The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2.
Jing-hui Tian +29 more
semanticscholar +1 more source
A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1985-1998, December 2022., 2022 Abstract Objectives Peripheral neuropathy is a relevant dose‐limiting adverse event that can affect up to 90% of oncologic patients with colorectal cancer receiving oxaliplatin treatment. The severity of neurotoxicity often leads to dose reduction or even premature cessation of chemotherapy.
Aina Calls +9 more
wiley +1 more source